Thyroid function was evaluated in 46 patients with end-stage kidney disease and 42 normal subjects. Patients were studied before and after the institution of maintenance hemodialysis (HD) and after renal transplantation (RT). Serum total triiodothyronine concentrations (TT 3 , ng/100 ml, mean±SD) were 63±17 and 83±22 in the non-HD and HD groups, respectively. Values from normal subjects were 128±25 and from RT patients 134±20. The TT 3 was in the hypothyroid range (<78 ng/100 ml; 2 SD below normal mean) in 80% of non-HD and 43% of HD patients. Mean serum total thyroxine concentration (TT 4 ), although within the normal range, was lower than the control value. T 4 -binding globulin capacity was also slightly lower but the difference was not statistically significant. Among patients whose TT 4 was 1 SD below the normal mean, the free T 4 index was equally depressed, suggesting that factors other than decreased binding capacity might be responsible for the low TT 4 . In addition, there was a 37% incidence of goiter. Mean serum thyroid-stimulating hormone (TSH) was not elevated and the TSH response to thyrotropin-releasing hormone (TRH) was distinctly blunted, suggesting the possibility of pituitary dysfunction as well. In vivo 125 I-l-T 4 and 131 I-l-T 3 kinetics during 0.2 mg/day of l-T 4 replacement showed marked reduction in T 3 turnover rate in the uremic patients, both before and during HD; the values (µg T 3 /day, mean±SD) for […] Find the latest version: (RT). Serum total triiodothyronine concentrations (TT3, ng/100 ml, mean± SD) were 63±17 and 83±22 in the non-HD and HD groups, respectively. Values from normal subjects were 128±25 and from RT patients 134±20. The TT3 was in the hypothyroid range (<78 ng/100 ml; 2 SD below normal mean) in 80% of non-HD and 43% of HD patients. Mean serum total thyroxine concentration (TT4), although within the normal range, was lower than the control value. T4-binding globulin capacity was also slightly lower but the difference was not statistically significant. Among patients whose TT4 was 1 SD below the normal mean, the free T4 index was equally depressed, suggesting that factors other than decreased binding capacity might be responsible for the low TT4. In addition, there was a 37% incidence of goiter. Mean serum thyroid-stimulating hormone (TSH) was not elevated and the TSH response to thyrotropinreleasing hormone (TRH) was distinctly blunted, suggesting the possibility of pituitary dysfunction as well. In vivo '25I-L-T4 and 13'I-L-T3 kinetics during 0.2 mg/day of L-T4 replacement showed marked reduction in T3 turnover rate in the uremic patients, both before and during HD; the values (,tg T3/day, mean±SD) for the different groups were as follows: normal, 33.8+6.1; non-HD, 13.5±2.6; HD, 12.9±3.1; and RT, 30.3±7.1.
normal subjects. Patients were studied before and after the institution of maintenance hemodialysis (HD) and after renal transplantation (RT) . Serum total triiodothyronine concentrations (TT3, ng/100 ml, mean± SD) were 63±17 and 83±22 in the non-HD and HD groups, respectively. Values from normal subjects were 128±25 and from RT patients 134±20. The TT3 was in the hypothyroid range (<78 ng/100 ml; 2 SD below normal mean) in 80% of non-HD and 43% of HD patients. Mean serum total thyroxine concentration (TT4), although within the normal range, was lower than the control value. T4-binding globulin capacity was also slightly lower but the difference was not statistically significant. Among patients whose TT4 was 1 SD below the normal mean, the free T4 index was equally depressed, suggesting that factors other than decreased binding capacity might be responsible for the low TT4. In addition, there was a 37% incidence of goiter. Mean serum thyroid-stimulating hormone (TSH) was not elevated and the TSH response to thyrotropinreleasing hormone (TRH) was distinctly blunted, suggesting the possibility of pituitary dysfunction as well. In vivo '25I-L-T4 and 13'I-L-T3 kinetics during 0.2 mg/day of L-T4 replacement showed marked reduction in T3 turnover rate in the uremic patients, both before and during HD; the values (,tg T3/day, mean±SD) for the different groups were as follows: normal, 33 .8+6.1; non-HD, 13 .5±2.6; HD, 12 .9±3.1; and RT, 30.3±7.1.
The low T3 turnover rate was due to impaired extrathyroidal conversion of T4 to T3. The mean per-cent±SD of metabolized T4 converted to T3 was 37.2±5.8 in normal subjects, 15.7±3.1 in non-HD, 12.8±1.7 in HD, and 34.0±14.7 in RT patients. In contrast, thyroidal T3 secretion rate was not different between the control and the three patient groups.
Thus, it appears that uremia affects thyroid function at several levels: (a) subnormal pituitary TSH response to TRH; (b) possible intrathyroidal abnormalities as suggested by slightly decreased TT4 and high incidence of goiter; and (c) abnormal peripheral generation of T3 from T4. Restoration of renal function with RT resulted in normalization of all parameters of thyroid function with the exception of blunted or absent TSH response to TRH. The latter may be a direct consequence of glucocorticoid administration.
INTRODUCTION
Patients with chronic renal failure often exhibit clinical features and laboratory findings suggestive of hypothyroidism. Despite extensive studies, thyroid status in uremia is still inconclusive due to the complexity of the system studied. For example, thyroidal radioiodide uptake is decreased because of reduced renal iodide clearance (1, 2) . The serum hormonal concentration may be altered by changes in the binding capacity of serum proteins (3, 4) , and abnormal serum constituents in uremia were thought to displace thyroid hormone from its protein-binding sites (5) . Heparin, a standard hemodialysis (HD)' medication, has been shown to increase serum free thyroxine concentration (6, 7) . Peritoneal dialysis is an effective way of IAbbreviations used in this paper: HD, hemodialysis; RT, renal transplantation; TT3, serum total triiodothyronine; TT4 serum total thyroxine; T3, triiodothyronine; T4, thyroxine; FTI, free thyroxine index; TBG, thyroxine-binding globulin; TSH, thyroid-stimulating hormone; TRH, thyrotropin-releasing hormone; MCR, metabolic clearance rate; D, turnover rate.
The Journal of Clinical Investigation Volume 60 September 1977-522-534 removing thyroid hormones from the circulation (8, 9) . Goiter may be induced by the high serum level of inorganic iodide (1, 2, 10) or retention of goitrogenic substances normally excreted by the kidney (11) . Finally, malnutrition may be a contributing factor in altering thyroid function tests (12) .
This communication presents the results of our attempts to study systematically the pituitary-thyroid axis as well as the peripheral metabolism of thyroid hormones in 46 patients with irreversible renal failure, before and during HD, and after renal transplantation (RT). Since recent studies from our laboratory (13) and by others (14) (15) (16) have demonstrated a reduction in the serum concentration of total triiodothyronine (TT3), and since more than half of the circulating triiodothyronine (T3) is derived from conversion of thyroxine (T4) to T3 in the periphery (17) (18) (19) , emphasis was placed on the study of this particular pathway of T4 metabolism. Additional studies include measurements of serum concentrations of total thyroxine (TT4), TT3, free thyroxine index (FTI), thyroxine-binding globulin (TBG) capacity, thyroid autoantibodies, and thyroid-stimulating hormone (TSH) as well as TSH response to thyrotropin-releasing hormone (TRH). The results indicate that uremia affects thyroid function in several ways, the most important of which is a profound impairment of extrathyroidal conversion of T4 to T3 resulting in a selective reduction in serum TT3.
CLINICAL MATERIAL
46 patients (26 men and 20 women) with end-stage kidney disease were studied. Their ages ranged from 20 to 58 yr. The etiology of their renal failure included hypertensive nephrosclerosis, chronic glomerulonephritis, polycystic kidney disease, interstitial nephritis, and epithelial cell disease with glomerulosclerosis. 20 patients were studied before institution of HD, 37 during HD, and 11 after successful RT. 17 patients were studied more than once as they went through the various stages of treatment. At the time of this study, the mean duration of dialysis was 15 mo (range, 2-30 mo). Hemodialysis was performed three times weekly with EX-23 or EX-25 coil dialyzers. Of those patients studied before entrance into the dialysis program, blood samples were obtained during their clinic visits. In patients studied during maintenance HD, blood was routinely sampled immediately before HD and before heparin administration. After RT, blood samples were obtained periodically throughout the recovery phase, until thyroid function had either returned to normal or stabilized, representing a period of at least 6 mo. As both TT4 and TT3 increased progressively, only values that have reached a stable plateau were used in the computation of mean and standard deviation for this particular group. All renal failture patients received aluminum hydroxide, multivitamins, folic acid, and ferrous sulfate. In addition, many patients required antihypertensive medications including methyldopa, hydralazine, and propranolol. Patients who received Dilantin and androgens were excluded from this study. Diuretics were not prescribed. The RT subjects received prednisone and azathioprine in various doses. The control group consisted of 42 healthy subjects including laboratory personnel and blood donors. Their age and sex distribution were comparable to those of the patients.
The experimental protocol was approved by the Committee on Human Experimentation and the Committee on the Use of Radioisotopes of the University of Chicago Hospitals. Informed written consent was obtained from the patients as well as from the normal volunteers.
METHODS
Thyroid function tests. Serum TT4 was measured by the competitive binding procedure and the FTI was calculated (20) . The T4-binding capacity of TBG was measured by saturation (4) and the concentration of serum TT3 by double-antibody precipitation radioimmunoassay (21) . The T3 antiserum was supplied by Dr. Gerald Burke, Cook County Hospital, Chicago, Ill. The characteristics of this antiserum have been previously described (21) . The antibody was produced in the rabbit by immunization with T3 coupled to human serum albumin; T3 was displaced from serum TBG with 8-anilino-1-naphthalene sulfonic acid. The method was sensitive to detect 10 ng T3/100 ml of serum (21) . The intra-and inter-assay coefficients of variation were <5 and 15%, respectively. Both T4 and 3,3',5'-triiodo-L-thyronine (reverse T3) in amounts equivalent to 50 ,g/lOO ml and 1,000 ng/100 ml of serum did not cross-react with T3 in the radioimmunoassay. Further, 95-102% of known amounts of T3 added to the serum of normal and uremic subjects were recovered. Serum concentration of TSH was also measured by the double-antibody precipitation radioimmunoassay (22) Peripheral turnover kinetics of T4 and T3. The peripheral metabolism of T4 and T3 was studied simultaneously in 22 subjects: 5 healthy euthyroid volunteers, 12 uremic patients (4 before and 8 after institution of maintenance HD), and 5 patients after successful RT.
'25I-L-Thyroxine ('25I-T4) and 31I-L-triiodothyronine (31 I-T3) were purchased from Industrial Nuclear Co., Inc., St. Louis, Mo. Their specific activities were 100 and 85 IACi/,ug, respectively. The radiochemical purity ofboth T4 and T3 in the isotope preparations was tested by descending paper chromatography in tertiary amyl alcohol:hexane:ammonia (25) and found to be >95%. The labeled hormones were mixed in sterile saline containing 5% salt-poor normal human serum albumin (Cutter Laboratories, Berkeley, Calif.). The final mixture was passed through a Millipore filter (Millipore Corp., Bedford, Mass.). Each patient received 2 ml of the saline-albumin mixture containing 10 uCi of 125I-T4 and 20 ,utCi of 131I-T3. This solution was injected intravenously and blood samples were obtained from the contralateral arm before, at 5 min, and at 2, 4, 6, 8, and 24 h after injection. Thereafter, samples were obtained every 24-48 h for another 8-10 days. The sera were stored at -20°C and assayed in batches with appropriate standards. Radioactivity was determined in all serum samples. Stable TT4 and TT3 were measured in samples taken immediately before isotope injection and on days 1-3, 5, 7, and 9; the mean value for each individual subject was used for the calculation of various kinetic parameters. In the HD patients, the isotope was injected 1 to 2 h after completion of HD treatment. The 24-h sample, as well as the subsequent blood samples, were obtained immediately before HD. Because of these patients' tendency to retain fluid and hemodilution, which may reduce thyroid hormone concentrations, total serum protein content was determined in every sample by refractometry and corrections were made for both TT4 and TT3 concentrations as previously described (26) . We used the protein concentration in the sample taken immediately before isotopic injection as base line because that was the time most HD patients were closest to their dry weight. To suppress endogenous thyroid hormone secretion and prevent recirculation of the labeled iodine, all subjects received 0.2 mg of L-thyroxine (Synthroid, Flint Laboratories, Deerfield, Ill.) daily, beginning 7 days before isotope injection and during the entire study. Five drops of a saturated solution of potassium iodide was given 1/2 h before the administration of labeled hormones and was continued twice daily throughout the study period.
After completion of each study, 2 ml of each serum sample was subjected to trichloroacetic acid (TCA) precipitation and the radioactivity in the precipitates was counted for 10 min in a dual channel gamma spectrometer (Packard Instrument Co. Inc., Downers Grove, Ill.). Contribution of 1311 in the 125I channel as well as isotope decay were corrected by inclusion of appropriate standards. Only samples with isotope contents of at least fourfold the background were used in the calculations. Dose standards were prepared by addition of0. 1% ofthe dose to the preinjection serum sample ofeach patient and were subsequently handled in a manner identical to the postinjection samples.
The serum disappearance rate of TCA-precipitable 125I activity from days 1 to 10 was used to calculate the T4 kinetics. For calculation of T3 turnover kinetics, the disappearance rate ofTCA-precipitable l31I activity from days 1 to 3 was used. The fractional turnover, distribution space, and metabolic clearance rate (MCR) of T4 were calculated by the method of single compartment kinetics (27) . The MCR of T3 was calculated by the noncompartmental method (19, 28) . The turnover rate (D) of T4 and T3 was derived from the product of MCR and mean serum concentration of the respective iodothyronine. Assuming that during the study period administration of L-thyroxine completely suppressed endogenous thyroid hormone secretion, the production rate of T3 from monodeiodination of T4 in the peripheral tissue (percent conversion of T4 to T3) could be calculated (19) . The percent of administered T4 absorbed was also calculated as described by Surks et al. (19) .
Assuming that MCR ofT4 and T3, as well as the percent ofT4 to T3 conversion in each individual, were identical before and during T4 replacement, the T3 produced by monodeiodination and that derived from thyroidal secretion during the basal state (before T4 replacement) could be calculated by using serum TT4 and TT3 concentrations before T4 administration: T3 derived from T4 (,umol/day) = T4 turnover (,.mol/day) x % T4 --T3 conversion 100 and T3 derived from thyroidal secretion (jig/day) = Total T3 turnover (,ug/day) -T3 derived from T4 (,ug/day).
The thyroidal secretion as percent of the total T4 turnover rate was also estimated.
Serum volume was estimated from the percent of the 12nI-T4 dose present in serum 5 min after injection of isotopes. Previous studies have shown that the dilutions of albumin and T4 are almost identical at this time of sampling and therefore the latter is suitable for measurement of serum volume (29, 30) .
Statistical analysis. All grouped data were expressed as mean±SD and were analyzed by the analysis of variance; mean square within value and paired t test were used to assess the statistical difference between any two means as indicated in the text (31) .
RESULTS
Thyroidfunction tests (Table I) . The most striking abnormality in the uremic patients was a reduction in serum TT3 concentration. The mean level of the combined non-HD and HD groups, 70 ngIlO0 mg, was 2 SD lower than the normal mean of 128 ng/100 ml. In fact, in 16 of 20 non-HD patients and in 16 of 37 HD patients, TT3 was 2 SD below the normal mean, i.e., <78 ng/100 ml. The mean values of TT4, FTI, and TBG capacity for the two groups of uremic patients were also reduced, but none of the differences reached statistical significance, with the exception of TT4 in the HD group. Both TT4 and TBG capacity were highly correlated in all four groups of subjects, the correlation coefficients (not shown in the tables) being as follows: normal, 0.820 (P < 0.001); before HD, 0.686 (P < 0.05); during HD, 0.665 (P < 0.01); and after RT, 0.827 (P < 0.02). In the two uremic groups there were 7 non-HD and 11 HD patients whose TT4 was <6.1 ,ug/100 ml (1 SD below normal mean); their corresponding FTI was also depressed, being 4 Effect of HD on thyroidftunction tests. 11 patients were studied both before and at least 2 mo after Table II . Hemodialysis resulted in only a slight increase in TT3 without significant change in other thyroid functions. Thyroid gland size and iodine content. Abnormal thyroid glands were found in 9 of 24 HD patients examined (37%). Two had nodular goiters and the other seven had diffusely enlarged thyroid glands. 14 HD patients were randomly selected for fluorescent thyroid scanning. The thyroidal iodine content estimated by this method was slightly decreased in two, normal in six, and markedly increased in the remaining six patients.
TRH stimulation test. After TRH injection, serum TSH concentration rose rapidly in seven normal subjects, reached a peak by 30 min, and returned to basal levels in 3 h. Of the seven HD patients tested, one showed no increase in serum TSH concentration, four had a blunted response, and the other two showed a low normal response. In the latter, the peak was delayed until [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] min, and TSH levels remained elevated for more than 3 h (Fig. 2) . The basal TSH value was normal in both the control and the uremic subjects, but the latter appeared to be lower. After TRH injection, serum TT3 concentration increased in five HD patients and was unchanged in the other two. The mean basal value was 72.1 and rose to 93.3 ng/ 100 ml, representing an increment of 28%. The difference between these two means as computed by paired t test was significant at <0.05 level. Of three RT subjects, 1 showed a blunted response and the other two failed to show any serum TSH increment (Fig. 3) . Despite minimal or no serum TSH elevation, serum TT3 increased from a mean base line of 155 to 187 ng/ 100 ml, a 21% increment; the difference was not significant.
Peripheral turnover kinetics of T4and T3. Time (min) FIGURE 2 Serum TSH response to 400 ,ug of TRH given intravenously in seven HD patients as compared to that of seven normal subjects whose ranges are represented by the shaded area. subject studied, as well as mean values and statistical analyses. Administration of L-T4 elevated to a variable extent the serum TT4 concentration in all subjects. In some, TT4 increased to above 9.4 ,ug/100 ml, the upper limit of normal. There was no correlation between the TT4 concentration before and during L-T4 replacement. In contrast, the incremental rise in TT3 concentration during L-T4 replacement was proportional to the pretreatment TT3 value in all subjects from the four groups, r = 0.934, P < 0.001 (Fig. 4) . Thus, although serum TT3 increased after L-T4 treatment in all uremic patients, in most it remained in K and a slightly higher DS in the non-HD uremic below the normal mean of 128 ng/100 ml. In normal patients. This is probably due to the distribution of subjects and RT patients, serum TT3 increased often the labeled hormone into a large extracellular volume.
to above 160 ngIlO0 ml, the upper limit of normal. As a result of these reciprocal changes, the T4 turnover Individual fluctuations in serum TT4 and TT3 through-rate remained within normal limits. The MCR and D out the turnover study showed no distinct trend, of the HD uremic patients were normal, but there was indicating that a steady state has been achieved. a trend for the fractional turnover to be lower and Also shown in Table III is the absorption rate of for the DS to be higher. The two patients who had the exogenous T4 in uremic subjects, which ranged from largest distribution space also had the largest serum 31 to 84%. These values are compatible with data volume. The T4 kinetics of RT subjects were similar obtained by Surks et al. (19) and by Hays (32) in to that of controls. normal subjects. The RT patients also absorbed L-T4
In contrast to the T4 kinetics, T3 kinetics were normally.
distinctly abnormal in both groups of uremic patients. The parameters of T4 metabolism were similar in The mean serum TT3 concentration, T3 turnover rate, all groups studied with the exception of a decrease and percent T4 to T3 conversion were drastically Thyroid Dysfunction in Chronic Renal Failure 527 TT4 (pg/100 ml) 
DISCUSSION
These studies demonstrate that disturbances of thyroid function, the most important of which is a marked reduction in serum TT3 concentration, are common in chronic renal failure. Decreased serum TT3 was previously reported by us (13) and by Silverberg et al. (14) and was subsequently confirmed by several other investigators (15, 16, 33, 34) . Circulating TT3 was reduced into the hypothyroid range (<78 ng/100 ml) in 80% of the non-HD and 43% of the HD patients. While L-T4 administration effectively raised serum TT4 to levels often above the normal range, TT3 remained subnormal. This observation, coupled with the high TT4/TT3 ratio in the serum, suggested that low TT3 concentration in uremia may represent a selective deficiency. In our patient population, low TT3 could theoretically result from removal of circulating hormone through HD, decreased T3-binding capacity, increased hormone catabolism, reduced thyroidal T3 secretion, and lastly, diminished extrathyroidal T4 to T3 conversion. The results of our studies provide evidence for the latter mechanism.
Peritoneal dialysis has been shown by Hermann et al. to be effective in removing T4 in patients with thyrotoxic storm (8) and in rats made thyrotoxic by hormone administration (9) . There are no data showing a decrease in serum TT4 after conventional HD, using either cuprophane or cellulose membrane. Both Carter's report (15) and our study of the uremic patients before and 2 mo after institution of HD failed to show significant changes in the serum TT4 and FTI (Table  II) . On the contrary, serum-free T4 was reported to be higher after HD, an effect attributed to heparin (7, 35) , which is known to alter hormone binding and increase the concentration of free T4 (6).
Although we have not measured circulating free T3, Carter et al. (15) , in a report of T3 deficiency syndrome associated with a variety of nonthyroidal diseases, including renal failure, found that free T3 and TT3 were similarly decreased. Chopra et al. (16) , in a study of the low T3 syndrome with liver and kidney diseases, also reported that free T3 was significantly reduced. Bermudez et al. (36) described 24 patients with decreased serum T3 concentrations without thyroidal disease; 8 were due to low T3-binding capacity, 5 were attributable to their advanced age, and the remaining 11 were unexplained. Spector et al. reported that 54% of renal failure patients had low serum-free T3 concentrations (33) . If our finding of low TT3 concentration was due entirely to decreased binding capacity, it should have affected TT4 to a greater extent. Furthermore, changes in TBG capacity were small and statistically not significant. The fact that TT4/TT3 ratio was markedly elevated in our patients suggests that factors other than low binding capacity must be responsible for the low T3 deficiency.
Our kinetic studies showed that T3 degradation was not accelerated. In fact, the mean MCR was slightly decreased in both groups ofuremic patients. As for the mean T3 secretion by the thyroid gland, it ranged only from 1.7 to 3.7 ,ug/day in the four groups of subjects-representing only 7-14% of the total daily turnover in normal subjects. Hence, the observed depression in serum TT3 concentration cannot be explained on the basis of reduction, or even cessation, of thyroidal T3 secretion. Actually, the mean percentage of thyroidal T3 contribution to the overall amount of T3 metabolized was higher in patients with renal failure because of the marked reduction in their total T3 turnover rate. The T3 degradation was drastically reduced to about 40% of control value. The mean percent of metabolized T4 converted to T3 was decreased to approximately one-third of normal. Since under our experimental conditions it could be assumed for practical purposes that the only source of T3 was from extrathyroidal monodeiodination of T4, these results indicate that uremic patients have a profound impairment in the ability to generate T3 from T4. This conclusion is in agreement with the observation that their serum TT3 remained subnormal when serum TT4 was raised after L-T4 replacement.
Surks and co-workers have shown that a portion of radioiodine-labeled T3 administered to animals or humans is present in serum and tissue in a TCAprecipitable but ethanol nonextractable form. It has turnover kinetics different from T3 and a more prolonged half-life of 14 days (37, 38) . If not accounted for, especially in samples obtained 2 or more days after administration of the tracer, it may lead to falsely high 31I-T3 concentrations and consequently underestimation of MCR for T3. A comment is therefore in order to validate our T3 kinetic study, which did not take into account the nonextractable form of iodine. We believe that our observations are valid for several reasons: (a) In the plotting and calculation of MCR, we used only samples obtained up to 48 h when nonextractable iodine represents a relatively small fraction of serum TCAprecipitable radioactivity. (b) The MCR of T3 (18.6 liters/day) in our control subjects was comparable to that reported by Nomura et al. (39) , Surks et al. (19) , and Inada et al. (40) . (c) The magnitude of suppression of T3 turnover rate was so striking that even with a 10% correction for possible underestimation of MCR, the daily degradation would still be subnormal. Analogous to our results, in cirrhotic patients studied by Nomura et al. (39) , MCR was only minimally decreased, but the T3 disposal rate was markedly reduced due to the low serum TT3 concentration.
Our studies do not indicate whether the defect in peripheral T3 generation is due to the reduction of functioning renal tissue, to the metabolic derangement of uremia, or to the nonspecific effect of chronic illness. Experimental evidence of T3 production from monodeiodination of T4 has been obtained in various tissues (25, 41, 42) , including the kidney (43) . In our patients with renal failure, it does not appear that the conversion defect can be attributed to the lack of renal tissue, as serum TT3 concentration was not reduced further in anephric patients. A preponderant decrement in serum TT3 has been shown to occur in a variety of nonrelated chronic illnesses including liver cirrhosis, chronic obstructive pulmonary disease, disseminated malignancy, and malnutrition (15, 16, 36, 44) . Diminished peripheral conversion of T4 to T3 is responsible for the decreased serum TT3 concentration in patients with liver failure (39) and starvation (45) (5) . In the 46 patients that we studied, only one had serum albumin lower than 3.5 g/100 ml, and TBG capacity was not significantly different from normal. Of those patients whose TBG capacity was decreased, their TT4 was always low, but low TT4 was not necessarily accompanied by a reduction in TBG capacity, suggesting that factors other than decreased binding might, in part, be responsible for the slightly decreased serum TT4 concentration observed in some patients. Despite a marked reduction in the amount of T4 converted to T3 in patients with renal failure, the mean T4 D was not decreased, indicating that other metabolic pathways of degradation were not inhibited. The possibility that monodeiodination occurred preferentially in the inner benzene ring, resulting in the formation of reverse T3, should also be considered, as Chopra et al. (16) found that the serum reverse T3 concentration was elevated in patients with renal failure.
A 37% incidence of goiter is considerably higher than expected for the Chicago area. Increased frequency of goiter in uremia was first described by Ramirez et al. (11) and was confirmed by Zerefos et al. (47) in an autopsy series. Thyroid enlargement could result from increased TSH stimulation related to excessive iodine accumulation, or the presence of goitrogenic substances. In a preliminary communication, we reported slightly elevated TSH levels in patients with renal failure (13), but we found subsequently that our anti-human TSH serum had considerable cross-reactivity with luteinizing hormone. Since we modified our assay procedures by prior absorption with human chorionic gonadotropins, the TSH values of our uremic patients had been consistently normal. Normal TSH values in renal failure were also reported by Silverberg et al. (14) and by Ramirez et al. (11) .
Renal failure patients tend to retain iodide as shown by their high plasma inorganic iodide level (1, 2, 14) . Our finding of increased iodine content in the thyroid gland suggests that there might be a causal relationship between the high iodide stores and the increased incidence of goiter in uremia, particularly in the Chicago area, where the average dietary iodine intake is 420 ug/day.2 Ramirez et al. (11) proposed that retention of unknown goitrogens might be the explanation, and more recently Grantham et al. reported that aryl acid was markedly elevated in uremic patients and suggested that these aromatic compounds might be potentially goitrogenic (34, 48) .
Although low T3 syndrome is now well recognized in uremia, its significance remains unclear. Assuming that T3 is responsible for about one-half to two-thirds of the metabolic effects of the thyroid hormones (49) , it is surprising that T3 deficiency of the magnitude observed in our patients does not produce clinical hypothyroidism. In fact, studies designed to evaluate the metabolic effects of thyroid hormones in uremia have not revealed any abnormal results (33) . Nevertheless, one should be cautious in interpreting some of these findings, since uremia per se or the presence of an arteriovenous fistula may alter some of the commonly used clinical tests of thyroid function such as basal metabolic rate and QKd interval measurements. The absence of TSH elevation is generally regarded as evidence against hypothyroidism, yet hypothalamo-pituitary dysfunction may also be present, as suggested by the subnormal TSH response to TRH. The delayed peak response and sustained elevation might be related to the decreased renal clearance of either TSH (50) or TRH (51) . Blunted TSH secretion after TRH administration was also reported by Ramirez et al. (52) , Alvarez-Ude et al. (53) , and Czernichow et al. (54) . Furthermore, abnormal prolactin (55) and growth hormone (56) secretion, as well as inadequate gonadotropin compensation (57), have been demonstrated in patients with renal insufficiency.
We have not fully assessed the functional integrity of the thyroid gland. The T3 increment of 20 ng/100 ml or 28% after TRH administration was lower than that reported by Chopra et al. (58) in normal individuals, who at the end of 2 h had a mean T3 increment of 63 ng/100 ml serum, representing a 70% rise over base line. The smaller rise in serum TT3 may not represent an intrinsic thyroid abnormality as their TSH response to TRH was subnormal. Ramirez et al. (52) , however, reported that serum TT4 and TT3 increments after exogenous TSH administration were less than in controls, suggesting intrinsic thyroidal dysfunction.
After RT, serum thyroid hormone concentrations became normal. The rise in serum TT4 was in part due to higher TBG capacity while the increase in serum TT3 was due mostly to improved peripheral T4 to T3 conversion. The two patients whose T3 turnover and T4 to T3 conversion rates were the lowest also had the poorest renal function, their serum creatinine being >2 mg/100 ml. With restoration of renal function, serum creatinine fell precipitously, but serum TT3 rose very slowly over a period of 3-4 mo. Before this, however, serum TT3 transiently decreased to below the pretransplant value, a possible consequence of the high-dose steroid treatment. Glucocorticoids are known to affect thyroid function by inhibition of extrathyroidal T4 to T3 conversion (59), decreased basal TSH secretion and TSH response to TRH stimulation (60, 61) , and possibly suppression of TRH as well (62) . When the dose of prednisone was tapered, circulating thyroid hormones gradually increased, but TSH response to TRH remained subnormal.
In summary, these studies indicate that uremia affects thyroid function at multiple levels: (a) There is a blunted TSH response to TRH, suggesting pituitary dysfunction or hypersensitivity to hormonal feedback. (b) There may be an intrathyroidal defect in hormonogenesis, hormonal secretion, or both, as evidenced by high incidence of goiter, increased thyroidal iodine content, and, in some patients, low serum TT4 not accountable for by depressed TBG capacity. The subnormal TT4 response to exogenous TSH administration reported by Ramirez et al. (52) lends support to this possibility. (c) Abnormal peripheral metabolism is characterized by a profound impairment of T4 to T3 conversion in extrathyroidal tissues, which results in a selective and marked reduction in serum TT3 concentration. The metabolic significance of these abnormalities remains unclear and deserves further study.
